SCHEMBL4021150

SCHEMBL4021150

Cc1c(C(=O)N(C)C)cc(C(=O)NCc2ccc(F)c(F)c2)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.53

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ELANE P08246 6/20 0.53
CCR1 P32246 8/20 0.51
NOTUM Q6P988 1/20 0.43
ALDH1A1 P00352 1/20 0.43
DDT P30046 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
PDE10A Q9Y233 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021451 0.89 ELANE (0.56) ELANECCR1NOTUMALDH1A1DDT
SCHEMBL4024041 0.89 CCR1 (0.54) ELANECCR1NOTUMALDH1A1DDT
SCHEMBL11894815 0.87 ELANE (0.54) ELANECCR1NOTUMALDH1A1DDT
SCHEMBL29875592 0.86 ELANE (0.53) ELANECCR1NOTUMALDH1A1
SCHEMBL4022960 0.86 ELANE (0.55) ELANECCR1
SCHEMBL4023968 0.86 ELANE (0.53) ELANECCR1NOTUMALDH1A1
SCHEMBL4019562 0.86 PPARG (0.53) ELANECCR1ALDH1A1LMNAHPGD
SCHEMBL11895082 0.85 ELANE (0.53) ELANECCR1NOTUM
SCHEMBL11895339 0.85 ELANE (0.50) ELANECCR1NOTUMALDH1A1DDT
SCHEMBL11894880 0.84 SORT1 (0.52) ELANECCR1ALDH1A1DDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11559520-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof AVALYN PHARMA INC. (US) 2023-01-24 US disclosed
US-20210069165-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC. (US) 2021-03-11 US disclosed
US-10092552-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof AVALYN PHARMA INC. (US) 2018-10-09 US disclosed
US-20170224706-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF GENOA PHARMACEUTICALS, INC. 2017-08-10 US disclosed
US-20120192861-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF GENOA PHARMACEUTICALS, INC. (US) 2012-08-02 US disclosed
EP-1663974-B1 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE ASTRAZENECA AB (SE) 2009-01-14 EP disclosed
US-20070043036-A1 2-Pyridone derivatives as neutrophil elastase inhibitors and their use ASTRAZENECA AB (SE) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210069165-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK ELANE 1574/4885CCR1 1988/4885NOTUM 4443/4885
US-20070043036-A1 2-Pyridone derivatives as neutrophil elastase inhibitors and their use SERPINB1, ELANE, SERPINE1 ELANE 2/4885CCR1 211/4885NOTUM 3343/4885
US-11559520-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof PLPBP, PIR, PDXK ELANE 1574/4885CCR1 1988/4885NOTUM 4443/4885
US-20120192861-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK ELANE 1574/4885CCR1 1988/4885NOTUM 4443/4885
US-20170224706-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK ELANE 1574/4885CCR1 1988/4885NOTUM 4443/4885
US-10092552-B2 Aerosol pirfenidone and pyridone analog compounds and uses thereof PLPBP, PIR, PDXK ELANE 1574/4885CCR1 1988/4885NOTUM 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.